Category
Clinical trials
Trial design and trial results are where value claims start. This coverage follows pivotal readouts, trial methodology and the evidentiary standards regulators and HTA bodies apply to them.
440 articles in this topic.
Articles in this category

11/17/2026
Three-Month Dapivirine Vaginal Ring Receives Positive EMA Opinion
The three-month dapivirine vaginal ring has received a positive EMA scientific opinion, with the ring replaced four times per year. #SyenzaNews #HIVprevention #MarketAccess
Read Article →
11/17/2026
Povorcitinib for Hidradenitis Suppurativa: CHMP Recommends Povofortay
The CHMP has recommended povorcitinib for hidradenitis suppurativa as Povofortay, a JAK1 inhibitor for adults who responded inadequately to, or are intolerant or contraindicated to, anti-TNF therapy.
Read Article →
11/17/2026
FDA Rejects Ivonescimab Lung Cancer Treatment Over Survival Gap
FDA rejects ivonescimab lung cancer treatment: the trial slowed progression, but the overall survival benefit did not reach statistical significance.
Read Article →
11/17/2026
EMA Recommends Gazyvaro for Systemic Lupus Erythematosus: What the Trial Shows
EMA recommends Gazyvaro for systemic lupus erythematosus after a 303-patient trial showed 76.7% response on add-on therapy versus 53.5% on placebo.
Read Article →
11/16/2026
CHMP November 2026 Recommends Seven New Medicines for Approval
EMA's CHMP recommended seven new medicines and 11 indication extensions at its 9 to 12 November 2026 meeting, and confirmed two refusals after re-examination.
Read Article →
11/16/2026
Baxfendy EU Positive Opinion: CHMP Backs AstraZeneca’s Hypertension Tablet
The CHMP recommended granting a marketing authorisation for AstraZeneca's Baxfendy (baxdrostat) for insufficiently controlled hypertension. The European Commission makes the final decision. #SyenzaNews #MarketAccess
Read Article →
11/13/2026
Appropriate Comparator Use for EMA-Approved Drugs Fell From 2011 to 2024
Only 58% of EMA-approved drug indications from 2011 to 2024 had at least one trial population tested against an appropriate comparator. The share fell from 78% of 2011 to 2012 approvals to 39% of 2023 to 2024 approvals. #SyenzaNews #MarketAccess
Read Article →
11/12/2026
Aspen Gets Approval for Generic Semaglutide in Brazil and South Africa
Aspen Pharmacare has received approval for generic semaglutide in Brazil and South Africa, following Canada in July. Launches in all three markets are expected over the coming months. #SyenzaNews #MarketAccess
Read Article →
11/10/2026
Factor XIa Inhibitor for Stroke Prevention: FDA Approves Sunharbo
The FDA approved Sunharbo (asundexian), the first factor XIa inhibitor for stroke prevention, for adults after a recent ischemic stroke or high-risk TIA. #SyenzaNews #MarketAccess
Read Article →
11/6/2026
M72 tuberculosis vaccine approval in Indonesia: BPOM weighs a fast track
BPOM is drafting a conditional approval route for the M72 TB vaccine and a joint review with the European Medicines Agency, ahead of Phase 3 results.
Read Article →
11/4/2026
Truqap prostate cancer withdrawal: AstraZeneca pulls EU bid
"Truqap prostate cancer withdrawal: AstraZeneca pulled its EU bid for newly diagnosed use after EMA raised benefit-risk concerns." #SyenzaNews #MarketAccess
Read Article →
11/3/2026
FDA Potency Assurance Guidance: What It Asks of Cell and Gene Therapy Makers
FDA has finalized its potency assurance guidance for cell and gene therapy products. It covers lot-release testing, potency assays, acceptance criteria and how sponsors should build a strategy from the IND stage onward. #SyenzaNews #CellAndGeneTherapy #FDA
Read Article →


